Supplementary Methods from Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube–Derived High-Grade Serous Ovarian Cancers

Karst, Alison M.; Jones, Paul M.; Vena, Natalie; Ligon, Azra H.; Liu, Joyce F.; Hirsch, Michelle S.; Etemadmoghadam, Dariush; Bowtell, David D.L.; Drapkin, Ronny

doi:10.1158/0008-5472.22402541.v1

- No file added yet -

Supplementary Methods from Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube–Derived High-Grade Serous Ovarian Cancers

journal contribution

posted on 2023-03-30, 22:34 authored by Alison M. Karst, Paul M. Jones, Natalie Vena, Azra H. Ligon, Joyce F. Liu, Michelle S. Hirsch, Dariush Etemadmoghadam, David D.L. Bowtell, Ronny Drapkin

PDF file - 75K, FISH (fluorescence in situ hybridization) analysis of TMA and Western blot analysis.

History

ARTICLE ABSTRACT

The fallopian tube is now generally considered the dominant site of origin for high-grade serous ovarian carcinoma. However, the molecular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few experimental studies examining the transformation of human fallopian tube cells. Prompted by recent genomic analyses that identified cyclin E1 (CCNE1) gene amplification as a candidate oncogenic driver in high-grade serous ovarian carcinoma, we evaluated the functional role of cyclin E1 in serous carcinogenesis. Cyclin E1 was expressed in early- and late-stage human tumor samples. In primary human fallopian tube secretory epithelial cells, cyclin E1 expression imparted malignant characteristics to untransformed cells if p53 was compromised, promoting an accumulation of DNA damage and altered transcription of DNA damage response genes related to DNA replication stress. Together, our findings corroborate the hypothesis that cyclin E1 dysregulation acts to drive malignant transformation in fallopian tube secretory cells that are the site of origin of high-grade serous ovarian carcinomas. Cancer Res; 74(4); 1141–52. ©2013 AACR.